Evaluatie van een nieuwe optische beeldvormingstechniek voor de detectie van het mammacarcinoom bij patiënten met borstkanker.

Rationale: ICG is a blood pool agent which is expected to delineate tumours by the fact that there are leaky vessels originating from angiogenesis from which the compound leaks into the tumour and surrounding tissue. After intravenous injection of ICG, tumour cells may be detected and visualized with a near-infrared fluorescence (NIRF) optical imaging system, thereby offering the surgeon real-time intra-operative information on tumour location and margin status without changing the surgical procedure itself. It is expected that optical imaging will enable the surgeon to detect (diagnostic) and at the same time excise (therapeutic) malignant tissue and any residual disease during breast-conserving surgery, thereby decreasing the number of re-excisions needed after BCT. This pilot study is designed to determine the feasibility of a novel optical imaging device enhanced with ICG for the intra-operative detection of breast carcinoma. Subsequently, this might provide a platform technique for patient tailored surgical interventions and tumour-specific contrast agents in the future.

This pilot study hypothesizes that ICG enhanced near-infrared fluorescence (NIRF) optical imaging enables the intra-operative detection of breast carcinoma in breast cancer patients.

Day of surgery.

At the start of the surgery and during anesthesia, the patient receives an intravenous injection with ICG compound in the cephalic vein. The lumpectomy procedure is followed in accordance with conventional guidelines. During the actual lumpectomy, the presence of ICG leakage in the tumour vasculature is assessed by holding a near-infrared fluorescence optical imaging device directly above (~20 cm) the region of interest (operative field).